Assessment of nebulisation of sodium ceftiofur in the treatment of calves naturally infected with bovine respiratory disease

Twelve screened cases of bovine respiratory disease (BRD) in calves were enrolled. Six of the calves were treated intramuscularly with sodium ceftiofur (1 mg/kg), and six were treated with nebulised sodium ceftiofur (1 mg/kg). Comparative evaluation of the two therapeutic modalities was based on repetitive analysis of hematological profile of calves on days 0, 5, and 10 post-therapy. The mortality rate in the group of calves treated with the nebulised sodium ceftiofur was significantly (p?<?0.001) lower, and their clinical and hematological parameters returned to normal significantly (p?<?0.001) faster than in calves treated intramuscularly. Nebulisation of sodium ceftiofur is the most effective treatment in calves with BRD under field conditions. Nasal lavage fluid analysis indicating a high rise of neutrophil count and macrophages may be used as an alternative method to detect pulmonary inflammation in BRD-affected calves.     

A comparison of trimethoprim-sulfadoxine and ceftiofur sodium for the treatment of respiratory disease in feedlot calves

A field trial was performed to compare trimethoprim-sulfadoxine to ceftiofur sodium in the treatment of bovine respiratory disease (BRD) in feedlot calves. Five-hundred-and-fifty-five recently weaned, crossbred beef calves, with naturally occurring cases of BRD, were randomly assigned to either trimethoprim-sulfadoxine or ceftiofur sodium treatment groups. The effectiveness of the antibiotics was assessed by comparing relapse rates, three day treatment response rates, mortality rates, chronicity rates, and wastage rates. There was no statistical difference in the first or second relapse rates between the two groups. For the initial therapy, first relapses, and overall treatment episodes, a significantly greater proportion of the calves treated with ceftiofur sodium responded to three days of therapy than those treated with trimethoprim-sulfadoxine (p < 0.05). This resulted in a 10% reduction in treatment costs for calves in the ceftiofur group. There were significantly lower mortality and wastage rates attributable to BRD in the ceftiofur sodium group than in the trimethoprim-sulfadoxine group (p < 0.05). However, there were no significant differences in overall mortality, overall chronicity, or overall wastage rates between the treatment groups.     

Treatment of respiratory infections in horses with ceftiofur sodium.

Ceftiofur sodium was evaluated as a therapy for respiratory infections in horses. This cephalosporin antimicrobial was administered intramuscularly every 24 h and at a dose of 2.2 mg/kg (1.0 mg/lb) of body weight. The efficacy of ceftiofur sodium was compared with that of a positive control drug, ampicillin sodium (recommended dose of 6.6 mg/kg [3 mg/lb], given every 12 h). Both treatments were continued for 48 h after clinical symptoms were no longer evident (maximum of 10 days). Fifty-five (55) horses with naturally acquired respiratory infections were included in the study; 28 were treated with ceftiofur and 27 with ampicillin. Clinical improvement was recorded for 92.9% of the patients treated with ceftiofur and 92.6% of the animals receiving ampicillin. Both therapies reduced body temperatures to an afebrile level after 2 days of treatment. Complete recovery/cure was noted for 78.6% of the ceftiofur patients and 59.3% of the horses treated with ampicillin. Supporting variables (depression/malaise, respiration/dyspnoea, nasal discharge) were assessed and these also substantiated the effectiveness of the treatments. Both antibiotics were well tolerated. Neither pain nor swelling were noted at the ceftiofur injection site(s). None of the animals developed diarrhoea. Data from this study indicated that ceftiofur sodium is an effective and safe treatment for respiratory infections in horses.     

Comparative plasma pharmacokinetics of ceftiofur sodium and ceftiofur crystalline‐free acid in neonatal calves

The objective of this study was to compare the plasma pharmacokinetic profile of ceftiofur crystalline‐free acid (CCFA) and ceftiofur sodium in neonatal calves between 4 and 6 days of age. In one group (n = 7), a single dose of CCFA was administered subcutaneously (SQ) at the base of the ear at a dose of 6.6 mg/kg of body weight. In a second group (n = 7), a single dose of ceftiofur sodium was administered SQ in the neck at a dose of 2.2 mg/kg of body weight. Concentrations of desfuroylceftiofur acetamide (DCA) in plasma were determined by HPLC. Median time to maximum DCA concentration was 12 h (range 12–48 h) for CCFA and 1 h (range 1–2 h) for ceftiofur sodium. Median maximum plasma DCA concentration was significantly higher for calves given ceftiofur sodium (5.62 μg/mL; range 4.10–6.91 μg/mL) than for calves given CCFA (3.23 μg/mL; range 2.15–4.13 μg/mL). AUC_0‐∞ and Vd/F were significantly greater for calves given CCFA than for calves given ceftiofur sodium. The median terminal half‐life of DCA in plasma was significantly longer for calves given CCFA (60.6 h; range 43.5–83.4 h) than for calves given ceftiofur sodium (18.1 h; range 16.7–39.7 h). Cl/F was not significantly different between groups. The duration of time median plasma DCA concentrations remained above 2.0 μg/mL was significantly longer in calves that received CCFA (84.6 h; range 48–103 h) as compared to calves that received ceftiofur sodium (21.7 h; range 12.6–33.6 h). Based on the results of this study, CCFA administered SQ at a dose of 6.6 mg/kg in neonatal calves provided plasma concentrations above the therapeutic target of 2 μg/mL for at least 3 days following a single dose. It is important to note that the use of ceftiofur‐containing products is restricted by the FDA and the use of CCFA in veal calves is strictly prohibited.     

Efficacy of ceftiofur for treatment of experimental salmonellosis in neonatal calves

OBJECTIVE: To evaluate therapeutic efficacy of a high extralabel dose of ceftiofur for treatment of experimental salmonellosis in neonatal calves. ANIMALS: Forty-two 1- to 4-day-old Holstein bull calves. PROCEDURE: 36 calves were orally challenged with Salmonella enteritica serovar Typhimurium (6.5 x 10(8) colony-forming units). Six additional calves were retained as nonmedicated nonchallenged control calves. Four days following Salmonella challenge, surviving calves were randomly allocated to ceftiofur-treated (5 mg/kg, IM, q 24 h) or nonmedicated control groups. Calves assigned to the treated group were medicated daily for 5 days starting on day 4 after challenge. Calves were monitored for 18 days following Salmonella challenge. Outcome assessments included clinical parameters (attitude, appetite, fecal characteristics, and rectal temperature), mortality rate, and quantitative Salmonella culture of fecal samples, mesenteric lymph nodes, and cecal contents. RESULTS: Ceftiofur treatment was associated with a significant decrease in rectal temperature and diarrhea. Three of 15 medicated calves and 4 of 14 non-medicated calves died or were euthanatized between days 4 and 18. A significant decrease in fecal shedding of Salmonella organisms was observed in treated calves, compared with nonmedicated calves. Salmonella organisms were isolated from all 10 non-medicated calves at necropsy, whereas no Salmonella organisms were isolated from 5 of 12 medicated calves. CONCLUSIONS AND CLINICAL RELEVANCE: Treatment of salmonellosis in neonatal calves with a high extralabel dose of ceftiofur (5 mg/kg, IM, q 24 h) promotes animal welfare, reduces fecal shedding of Salmonella organisms, and may promote clearance of Salmonella infections when plasma ceftiofur concentrations are maintained above minimal inhibitory concentrations.     

Comparison of enrofloxacin and ceftiofur sodium for the treatment of relapse of undifferentiated fever/bovine respiratory disease in feedlot cattle

This commercial field trial compared the efficacy of enrofloxacin and ceftiofur sodium in beef cattle at high risk of developing undifferentiated fever (UF), also known as bovine respiratory disease (BRD) that received tilmicosin at feedlot arrival, were diagnosed and initially treated for UF with tilmicosin, and subsequently required a second UF treatment (first relapse). Feedlot cattle (n = 463) were randomly assigned to 2 experimental groups: ENRO or CEF. Second UF relapse, 3rd UF relapse, overall case fatality and BRD case fatality rates were lower in the ENRO group than in the CEF group (P < 0.05). There were no differences in average daily gain (allocation to re-implant date), chronicity, histophilosis case fatality or miscellaneous case fatality rates between the groups (P ≥ 0.05). A per-animal economic advantage of Can$57.08 was calculated for the ENRO group versus the CEF group. In feedlot cattle in western Canada at high risk of developing UF, it was more cost effective to administer enrofloxacin than ceftiofur sodium for treatment of UF relapse.     

Efficacy of tulathromycin or enrofloxacin for initial treatment of naturally occurring bovine respiratory disease in feeder calves

After undergoing arrival processing at one of two commercial feedlots, feeder calves with clinical signs of bovine respiratory disease (BRD) were randomly assigned to receive either tulathromycin (2.4 mg/kg SC) or enrofloxacin (12.5 mg/kg SC). Additional therapy for calves that did not respond to initial treatment followed a prescribed course. Initial treatment with tulathromycin resulted in significantly higher (P = .009 and P = .031 at sites 1 and 2, respectively) therapeutic success (87.9% and 80%, respectively) than did initial treatment with enrofloxacin (70.2% and 62.5%, respectively). Animals treated with tulathromycin also had fewer subsequent treatments and higher weight gains compared with those treated with enrofloxacin.     

Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves

The efficacy of tulathromycin in the treatment of bovine respiratory disease (BRD) due to Mycoplasma bovis was determined following experimental infection. Two highly pathogenic strains of M. bovis (with minimum inhibitory concentration values for tulathromycin of 1 and >64 microg/ml) were inoculated into 145 calves. Four days after inoculation, calves with clinical BRD were treated subcutaneously with saline or tulathromycin (2.5 mg/kg). Compared with saline, BRD-related withdrawals, peak rectal temperatures, and lung lesion scores were significantly lower for tulathromycin-treated calves (P < .01). Tulathromycin was highly effective in the treatment of BRD due to M. bovis in calves regardless of the minimum inhibitory concentration of the challenge strain (1 or >64 microg/ml).     

Efficacy of the morantel sustained release trilaminate matrix against gastrointestinal nematodes in beef calves

The effectiveness of the morantel sustained release trilaminate (MSRT) in controlling gastrointestinal nematodes through a grazing season was evaluated using 60 yearling beef stocker calves randomly divided into 2 groups of 30 animals each. In April 1985, the calves comprising the treatment group each received an MSRT designed to release morantel tartrate continuously for 90 days while those of the control group remained unmedicated. All animals were weighed and samples of rectal feces were taken at 14-day intervals, beginning on Day 0, until trial termination (Day 168). At trial termination, 10 control and 10 treated calves were necropsied for recovery of gastrointestinal nematodes. Three sets of parasite-na?ve tracer calves were utilized to evaluate the initial, interim and final levels of pasture contamination by nematode larvae. Overall, the use of the MSRT resulted in a 75.5% reduction (P less than 0.001) in output of nematode eggs from the principals, an 81.8% reduction (P less than 0.001) in numbers of gastrointestinal nematodes in principals (at trial termination), and a 96.9% reduction (P less than 0.05) of pasture larval nematode contamination (as indirectly indicated by parasite burdens in tracer calves). The mean weight advantage of treated calves was 16.6 kg per head (P less than 0.001).     

Efficacy of a 2-dose regimen of a sustained release ceftiofur suspension in horses with Streptococcus equi subsp. zooepidemicus bronchopneumonia

The efficacy and safety of sustained release ceftiofur administered twice, 4 days apart, for treatment of horses with naturally acquired Streptococcus equi subsp. zooepidemicus (Strep. zoo.) pneumonia was evaluated in a multicenter, placebo-controlled, double-blinded, randomized clinical trial. The study included 373 horses (278 treated and 95 placebos) with naturally acquired pneumonia. Inclusion in the statistical analyses for treatment efficacy for Strep. zoo. required recovery of ≥10(4) CFU/mL of Strep. zoo. on the primary isolation plate which resulted in 201 cases (145 treated and 56 placebos) with confirmed Strep. zoo. pneumonia evaluable for treatment success. Therapeutic success was defined by clinical improvement of lower respiratory tract infection at 4 and 9 days after initial dosing, resolution of clinical signs by 15 days, and no recurrence by 25 days. Of the 278 treated horses, 239 (85.9%) completed the 25 day study without additional therapy compared to 50 of the 95 (53.6%) placebo horses. In confirmed Strep. zoo. cases, a clinical cure was achieved in 66.9% of 145 treated horses compared to 32.1% of 56 placebo horses (P = 0.0286). Two doses of sustained release ceftiofur suspension were effective and safe in the treatment of naturally acquired lower respiratory tract infection associated with Strep. zoo. in horses under field use conditions.     

Efficacy of a novel sustained release anthelmintic device in preventing parasitic gastroenteritis in first-season calves

The efficacy of the first of a new generation of intraruminal devices for cattle, the morantel sustained release trilaminate, was assessed in two field trials. In each trial the animals were divided into a control group and a treated group. The device was administered to each calf before turn out in the spring and the reduction of gastrointestinal parasitism resulted in a substantial reduction in the level of pasture contamination with infective helminth larvae later in the season. Compared with the control calves the treated calves had a 94 per cent reduction of worm burdens acquired over the entire grazing season in the first trial, despite the controls being treated for clinical disease in September. In the second trial four anthelmintic treatments were administered to the control calves during the grazing season, but nevertheless a 64 per cent reduction of worm burdens in the treated group compared to the control group was recorded. The control of parasitic infection by the sustained-release devices resulted in mean weight gain advantages of 28.3 kg and 34.7 kg by the treated animals in the first and second trials respectively.     

Efficacy of morantel sustained release bolus against gastrointestinal nematodes in first season grazing Holstein calves

The efficacy of the morantel sustained release bolus (MSRB) in reducing gastrointestinal parasitism in first season grazing calves was evaluated during the summer--autumn grazing seasons of 1982 and 1983 in western Oregon. Each of 38 calves (1982) and 40 calves (1983) were randomly assigned to either control or treatment groups which were given MSRB on the day of turnout onto pasture. Mean worm burdens from tracer calves grazed with treated animals in 1982 and 1983 showed overall reductions of 86.4% (P greater than 0.05) and 84.3% (P less than 0.01), respectively, compared to tracers grazed with controls. Ostertagia ostertagi, Cooperia oncophora and Nematodirus helvetianus were the primary nematodes collected at necropsy. Twelve full-season 1982 tracer animals (6 treated and 6 control) indicated an 88.1% (P less than 0.05) overall reduction in mean worm burdens. Mean fecal worm egg per gram (EPG) counts of treated animals reflected a reduction of 69% (P less than 0.05) in 1982 and 90% (P less than 0.05) in 1983. Autumn inhibition of O. ostertagi was observed. In the 1982 trial the control animals showed a slight mean weight gain advantage over the treated group from Day 84 until Day 160 (trial termination) when the mean difference was 7.9 kg. The final mean weight gain advantage of treated animals in 1983 was 13.5 kg (P less than 0.05). These trials demonstrated that the MSRB was an effective anthelmintic for reducing gastrointestinal parasitism in grazing calves and for decreasing pasture larval contamination.     

Association of bovine respiratory disease with clinical status and acute phase proteins in calves

Eighty-four calves with respiratory disease from 18 herds in different parts of Finland were chosen for a study evaluating the capacity of different respiratory pathogens to cause changes in different acute phase protein concentrations, white blood cell (WBC) count and clinical signs. The selected acute phase proteins were fibrinogen, haptoglobin, serum amyloid-A, lipopolysaccharide binding protein and alpha1-acid glycoprotein. From each calf, a paired blood sample was obtained for serological studies of bovine parainfluenza virus-3, bovine respiratory syncytial virus, bovine coronavirus, bovine adenovirus-3 and bovine adenovirus-7. Tracheobronchial lavage was performed to detect bacteria and mycoplasma. Isolation of Pasteurella multocida was associated with increased concentrations of all tested acute phase proteins. For other pathogens, no significant relationships were observed. No association was present between viral or bacterial findings and WBC count.     

Efficacy of morantel sustained release trilaminate bolus against gastrointestinal nematodes in grazing dairy calves in Kenya

Summary The efficacy of morantel sustained release trilaminate (MSRT) bolus against gastrointestinal nematodes was evaluated under field conditions over a 10-month period. Twenty weaner calves were randomly divided into 2 groups of 10 calves each and grazed from March to December on adjacent, similarly contaminated paddocks. Group 1 calves (T-1) served as untreated controls while group 2 calves (T-2) were dosed at turnout with MSRT bolus designed to release morantel tartrate continuously for 90 days. The efficacy of MSRT was assessed by comparison of parasitological data (faecal worm egg counts, herbage larval counts, worm counts from tracer calves and set-stocked trial calves, determination of haematological parameters and pepsinogen levels), weight gains and clinical status of the animals. Faecal egg counts from the treated group (T-2) were reduced by 100% (P < 0·001) following treatment and remained significantly (P < 0·05) lower than counts from T-1 calves up to trial termination. The use of MSRT bolus resulted in a reduction of 92% (P < 0·001) in the number of gastrointestinal nematodes in set-stocked calves at the end of the study and a 55 to 85·7% reduction in herbage larval infectivity as reflected in lowered parasite burdens in tracer calves. At the trial termination, the control calves had gained on average (± s.d.) 59·4 ± 4·8 kg (200·0 ± 7·4 g day⁻¹) and the treated ones on an average 128·6 ± 10·5 kg (530·0 ± 13·1 g day⁻¹).

---

Eficacia De La Utilizacion De Bolos Trilaminados De Morantel Frente A Nematodos Gastrointestinales En Vacuno De Leche En Pastoreo En Kenya

Resumen Se evaluó la eficacia de los bolos trilaminados de liberación continua de morantel (MSRT) frente a nematodos gastrointestinales en condiciones de campo y durante un período de 10 meses. Un total de 20 terneros recién destetados fueron divididos al azar en dos grupos de 10 animales cada uno y mantenidos en pastoreo desde marzo hasta diciembre en parcelas adyacentes y con una carga parasitaria similar. Los terneros del grupo 1 (T-1) fueron los animales control y no recibieron ningun tratamiento, mientras que los terneros del grupo 2 (T-2) fueron tratados con MSRT al inicio del período de pastoreo; los MSRT estaban dise?ados para liberar tartrato de morantel de forma contínua durante 90 días. La eficacia de los MSRT se evaluó comparando datos parasitológicos (huevos en heces, larvas en el pasto, parásitos en los animales, parámetros hematológicos y niveles de pepsinógeno), ganancias de peso y datos clínicos. El número de huevos en heces en los animales T-2 se redujo en un 100% (P < 0·001) después del tratamiento y se mantuvo significativamente más bajo (P 0·05) que el de los animales T-1 durante todo el experimento. La utilización de MSRT resultó en una reducción del 92% (P < 0·001) en el número de nematodos gastrointestinales y en una reducción del 55 al 85·7% en el número de larvas en el pasto. La ganancia de peso final fue de 59·4 ± 4·8 kg en los animales T-1 (200·0 ± 7·4 g/día) y de 128·6 ± 10·5 kg en los animales T-2 (530·0 ± 13·1 g/día).

---

Efficacite Du Morantel Por Voie Orale Contre Des Nematodes Gastro-Intestinaux Chez Des Veaux Laitiers Au Kenya

Résumé L’efficacité du Morantel distribué par voie orale, contre des nématodes intestinaux fut évaluéein situ sur plus de 10 mois. 20 veaux sevrés furent répartis au hasard dans 2 groupes de 10 veaux chacuns et broutèrent de Mars à Décembre sur 2 parcelles adjacentes et contaminées de fa?on identique. Le premier groupe (T-1) servit de temoin alors que le deuxième groupe (T-2) re?ut du morantel de fa?on continue pendant 90 jours. L’efficacité du Morantel fut analysée par comparaison des données parasitologiques (nombre d’oeufs de nématode dans les faèces, nombre de larve dans l’herbe, nombre de nematodes chez des veaux de contr?le mobiles et non mobiles, determination des paramètres hématologiques et des tereurs en pepsinogène), des gains de poids et des caractéristiques cliniques des animaux. Le nombre d’oeufs dans les faeces furent réduits de 100% dans le groupe (T-2) (P < 0,001) après le traitement et perdura de fa?on significative (P < 0,05) en dessous des valeurs pour les veaux du groupe (T-1) et cela jusqu’à la fin de l’éxpérience. L’utilisation du Morantel par voie orale entra?na une réduction de 92% dans le nombre des nématodes intestinaux dans les veaux immobilisés à la fin de l’experimentation ainsi qu’une réduction de 55 à 85,7% des larves dans les herbages témoin d’une diminution des parasites rejetés par les animaux sentinels. A la fin de l’expérimentation, les veaux du groupe de contr?le gagnèrent en moyenne 59,4 kg ± 4,8 kg (200,0 ± 7,4 g/jour) alors que les animaux traités gagnèrent en moyenne 128,6 ± 10,5 kg (530,0 ± 13,1 g/jour).

     

Antimicrobial resistance in bovine respiratory disease: Auction market- and ranch-raised calves

This study compared changes in prevalence and antimicrobial susceptibility of Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in feedlot calves derived from the auction market (AUCT; n = 299) and from a single-ranch source (RANCH; n = 300). In the AUCT calves, the prevalence of Mannheimia haemolytica decreased, whereas Histophilus somni increased over the feeding period. The AUCT calves showed an increase in isolates not susceptible to tulathromycin for all bovine respiratory disease (BRD) pathogens, an increase in Pasteurella multocida and Histophilus somni isolates not susceptible to oxytetracycline, and an increase in Pasteurella multocida isolates not susceptible to florfenicol. In the RANCH calves, the prevalence of all 3 BRD pathogens was high at feedlot entry and decreased significantly during the study period. In RANCH calves, there was a significant increase in Pasteurella multocida isolates not susceptible to oxytetracycline, tulathromycin, and florfenicol. Surprisingly, there was a significant decrease in Mannheimia haemolytica isolates that were not susceptible to oxytetracycline, tilmicosin, and tulathromycin.     

我国14省市呼吸道综合征患牛冠状病毒感染的检测

牛冠状病毒(bovine coronavirus, BCoV)是导致牛消化道和呼吸道疫病的主要病原之一,其在国内养殖业的感染报道较少。本试验对牛冠状病毒感染情况及其与临床罹患呼吸道疾病综合征犊牛的临床症状相关性开展研究。在奶牛养殖量较大的14个省市随机选择29个规模化牧场,对未断奶的犊牛进行呼吸道疾病综合征评估,选取单一症状典型的犊牛采集血清和鼻咽拭子。在176份样品中BCoV阳性共38份,阳性率为21.59%。统计发现,采自黑龙江的病料中冠状病毒检出率最高(70%),新疆次之,山西、上海、安徽未检出BCoV阳性样品;阳性病例与呼吸道疾病疾病综合征临床症状的相关性分析表明,病畜的发热、鼻腔分泌物性状改变与感染牛冠状病毒密切相关。本研究为牛冠状病毒感染导致犊牛呼吸道疾病综合征的临床诊断提供了参考。